Online inquiry

IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13843MR)

This product GTTS-WQ13843MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets GCGR gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000160.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2642
UniProt ID P47871
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ13843MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11734MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MK-0646
GTTS-WQ11386MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI-573
GTTS-WQ7712MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GEXMab73
GTTS-WQ15861MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XmAb5871
GTTS-WQ8445MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HspE7
GTTS-WQ9488MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IPH-5401
GTTS-WQ14874MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ6422MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CT-P22
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW